董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Dobkin | 男 | Director | 42 | 未披露 | 未持股 | 2021-06-16 |
| Barry Dennis | 男 | Director | 56 | 未披露 | 未持股 | 2021-06-16 |
| Andreas Typaldos | 男 | Chairman of the Board, Chief Executive Officer, Secretary | 75 | 未披露 | 未持股 | 2021-06-16 |
| Sean Fitzpatrick | 男 | Chief Financial Officer, Director | 55 | 未披露 | 未持股 | 2021-06-16 |
| Robert Nicholson | 男 | Director | 47 | 未披露 | 未持股 | 2021-06-16 |
| William Carson | 男 | Director | 73 | 未披露 | 未持股 | 2021-06-16 |
| Anthony Hayes | 男 | Director | 53 | 未披露 | 未持股 | 2021-06-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andreas Typaldos | 男 | Chairman of the Board, Chief Executive Officer, Secretary | 75 | 未披露 | 未持股 | 2021-06-16 |
| Sean Fitzpatrick | 男 | Chief Financial Officer, Director | 55 | 未披露 | 未持股 | 2021-06-16 |
董事简历
中英对照 | 中文 | 英文- David Dobkin
-
David Dobkin，我们的首席财务官兼董事会成员（2019年6月以来），是一位经验丰富的Healthcare Capital市场投资银行家，其职业生涯专注于帮助高增长的生命科学、医疗设备和梦百合IT公司实现其财务和战略目标。David自2019年6月起担任特殊目的收购公司LifeSci Acquisition Corp.的首席财务官兼董事。他是在美国和加拿大各地的会议上关于增长资本形成的定期演讲人。加入LifeSci Capital之前，David曾担任Boustead Securities董事总经理。在此之前，David于2015年创立了Dobkin&Company，这是一家为企业家领导的公司量身定制的投资银行，专注于种子和成长股权和资本。此前，David从2010年到2015年在新西兰政府（New Zealand Government）担任多个职位，代表区域公司和政府机构促进资本形成，重点是确保战略性外国直接投资。2010年10月之前，他曾任职Lazard FR&232；res公司（世界卓越的金融咨询和资产管理公司之一），在那里他曾促进和建议超过25亿美元的跨境并购交易。在加入Lazard Fr&232；res之前，大卫在纽约Wasserstein Perella的梦百合投资银行集团开始了他的职业生涯。在Wasserstein Perella，David为梦百合公司提供资本形成和战略选择方面的建议。David进行干细胞生物工程研究生研究，并在南加州大学（University of Southern California）获得生物医学工程理学硕士学位。David还在Columbia University获得生物医学工程学士学位。David持有系列6379和82的许可证。
David Dobkin, has been our Chief Financial Officer and Board member since December 2019 and is an experienced healthcare capital markets investment banker with a career focused on helping high-growth life science, medical device, and healthcare IT companies achieve their financial and strategic goals. David was the Chief Financial Officer and a director of LifeSci Acquisition Corp., a special purpose acquisition company, from June 2019 until its merger with Vincerx Pharma Inc. in December 2020. David has experience with both traditional and non-traditional forms of equity and debt offerings in both the U.S. and abroad. He is a regular speaker on growth capital formation at conferences across the United States and Canada. Prior to joining LifeSci Capital, David was a Managing Director at Boustead Securities. Prior to that, in 2015 David founded Dobkin & Company, an investment bank tailored for entrepreneur-led companies focused on seed and growth equity and capital. Previously, David worked in various capacities with the New Zealand Government facilitating capital formation on behalf of regional companies and government agencies with a focus on securing strategic foreign direct investment. David has tremendous experience conducting cross-border transactions. Prior to October 2010 David worked for Lazard Frères, one of the world's preeminent financial advisory and asset management firms, where he facilitated and advised on cross-border mergers and acquisitions transactions in excess of $2.5 billion. Prior to joining for Lazard Frères, David began his career in the Healthcare investment banking group for Wasserstein Perella based in New York. At Wasserstein Perella, David advised healthcare companies on capital formation as well as strategic alternatives. David conducted graduate research in stem cell bioengineering and received a Master of Science, Biomedical Engineering, from the University of Southern California. David also received a B.S. in Biomedical Engineering, from Columbia University. David holds the Series 63 79 and 82 licenses. - David Dobkin，我们的首席财务官兼董事会成员（2019年6月以来），是一位经验丰富的Healthcare Capital市场投资银行家，其职业生涯专注于帮助高增长的生命科学、医疗设备和梦百合IT公司实现其财务和战略目标。David自2019年6月起担任特殊目的收购公司LifeSci Acquisition Corp.的首席财务官兼董事。他是在美国和加拿大各地的会议上关于增长资本形成的定期演讲人。加入LifeSci Capital之前，David曾担任Boustead Securities董事总经理。在此之前，David于2015年创立了Dobkin&Company，这是一家为企业家领导的公司量身定制的投资银行，专注于种子和成长股权和资本。此前，David从2010年到2015年在新西兰政府（New Zealand Government）担任多个职位，代表区域公司和政府机构促进资本形成，重点是确保战略性外国直接投资。2010年10月之前，他曾任职Lazard FR&232；res公司（世界卓越的金融咨询和资产管理公司之一），在那里他曾促进和建议超过25亿美元的跨境并购交易。在加入Lazard Fr&232；res之前，大卫在纽约Wasserstein Perella的梦百合投资银行集团开始了他的职业生涯。在Wasserstein Perella，David为梦百合公司提供资本形成和战略选择方面的建议。David进行干细胞生物工程研究生研究，并在南加州大学（University of Southern California）获得生物医学工程理学硕士学位。David还在Columbia University获得生物医学工程学士学位。David持有系列6379和82的许可证。
- David Dobkin, has been our Chief Financial Officer and Board member since December 2019 and is an experienced healthcare capital markets investment banker with a career focused on helping high-growth life science, medical device, and healthcare IT companies achieve their financial and strategic goals. David was the Chief Financial Officer and a director of LifeSci Acquisition Corp., a special purpose acquisition company, from June 2019 until its merger with Vincerx Pharma Inc. in December 2020. David has experience with both traditional and non-traditional forms of equity and debt offerings in both the U.S. and abroad. He is a regular speaker on growth capital formation at conferences across the United States and Canada. Prior to joining LifeSci Capital, David was a Managing Director at Boustead Securities. Prior to that, in 2015 David founded Dobkin & Company, an investment bank tailored for entrepreneur-led companies focused on seed and growth equity and capital. Previously, David worked in various capacities with the New Zealand Government facilitating capital formation on behalf of regional companies and government agencies with a focus on securing strategic foreign direct investment. David has tremendous experience conducting cross-border transactions. Prior to October 2010 David worked for Lazard Frères, one of the world's preeminent financial advisory and asset management firms, where he facilitated and advised on cross-border mergers and acquisitions transactions in excess of $2.5 billion. Prior to joining for Lazard Frères, David began his career in the Healthcare investment banking group for Wasserstein Perella based in New York. At Wasserstein Perella, David advised healthcare companies on capital formation as well as strategic alternatives. David conducted graduate research in stem cell bioengineering and received a Master of Science, Biomedical Engineering, from the University of Southern California. David also received a B.S. in Biomedical Engineering, from Columbia University. David holds the Series 63 79 and 82 licenses.
- Barry Dennis
-
Barry Dennis，自2020年3月起担任我们的董事会成员，是Wavecrest Securities的投资银行和战略咨询董事总经理。在2018年加入Wavecrest之前，Barry于2013年至2017年担任结构化产品对冲基金Strategos Capital Markets总裁。Barry还从1993年到2015年在Canaccord Genuity，Merrill Lynch，TD Securities和BMO任职。巴里在British Columbia大学获得商业学士学位，在西安大略大学获得工商管理硕士学位。
Barry Dennis,CFA, has served as a member of the Board Member as of the IPO. Barry is a Managing Director of Investment Banking and Strategic Consulting at WaveCrest Securities and since March 2020 Barry has been a member of the board of directors of LifeSci Acquisition Corp NASDAQ: LSAC, a blank check company that raised approximately $65600000 in its initial public offering and is currently seeking to consummate an initial business combination in the healthcare industry. Prior to joining WaveCrest, from January 2018 to December 2019 Barry served as Chairman of the Risk Committee Strategos Capital Markets, a structured products hedge fund, and as President from April 2015 to March 2017. From August 2013 to February 2015 Mr. Dennis served as Senior Managing Director of Institutional Structured Products for Canaccord Genuity, a full-service financial services firm and he served on Canaccord’s US Executive Management Committee in New York City. From 1993 to 2013 Barry worked for such firms as Merrill Lynch, TD Securities, and BMO. Barry received his Bachelor’s of Commerce from the University of British Columbia and his M.B.A from the University of Western Ontario and is a holder of the Charter of Financial Analysts. - Barry Dennis，自2020年3月起担任我们的董事会成员，是Wavecrest Securities的投资银行和战略咨询董事总经理。在2018年加入Wavecrest之前，Barry于2013年至2017年担任结构化产品对冲基金Strategos Capital Markets总裁。Barry还从1993年到2015年在Canaccord Genuity，Merrill Lynch，TD Securities和BMO任职。巴里在British Columbia大学获得商业学士学位，在西安大略大学获得工商管理硕士学位。
- Barry Dennis,CFA, has served as a member of the Board Member as of the IPO. Barry is a Managing Director of Investment Banking and Strategic Consulting at WaveCrest Securities and since March 2020 Barry has been a member of the board of directors of LifeSci Acquisition Corp NASDAQ: LSAC, a blank check company that raised approximately $65600000 in its initial public offering and is currently seeking to consummate an initial business combination in the healthcare industry. Prior to joining WaveCrest, from January 2018 to December 2019 Barry served as Chairman of the Risk Committee Strategos Capital Markets, a structured products hedge fund, and as President from April 2015 to March 2017. From August 2013 to February 2015 Mr. Dennis served as Senior Managing Director of Institutional Structured Products for Canaccord Genuity, a full-service financial services firm and he served on Canaccord’s US Executive Management Committee in New York City. From 1993 to 2013 Barry worked for such firms as Merrill Lynch, TD Securities, and BMO. Barry received his Bachelor’s of Commerce from the University of British Columbia and his M.B.A from the University of Western Ontario and is a holder of the Charter of Financial Analysts.
- Andreas Typaldos
-
Andreas Typaldos自公司成立起担任董事长兼首席执行官。安德烈亚斯从软件和技术行业一开始就是一位企业家，同时也是一家家族办公室的私人股本投资者。他的创业活动和公司遍及美国和国际，主要是欧洲。过去，他曾是许多软件，技术，咨询服务和互联网公司的创始人，创始投资者，董事会成员兼首席执行官，其中包括早期的国际企业软件公司AXS-One；Enikia LLC随后被称为Arkados和Iota Communications Inc.，Xandros Inc.是一家基于Powerline的通信领域的无晶圆厂半导体公司，在进入物联网领域之前，其兼容HomePlug的技术被出售给了最大的半导体公司之一（ST Micro），一家Linux操作系统公司，提供华硕和英特尔在EeePC上网本移动设备上使用的操作系统，以在被苹果iPad平板电脑统治之前创建该空间；以及技术，软件，AI和生活方式市场上的其他一些公司。目前，他是BCII Enterprises Inc.的执行主席，BCII Enterprises Inc.是一家上市控股公司，拥有许多软件，云和AI运营子公司，包括他担任董事长的数字健康和虚拟护理公司Soteria Health；和Scalix Inc.的执行主席，一家基于Linux的企业电子邮件服务器公司，由微软提供资金和技术支持。在生活方式和生命科学相关行业，他是早期癌症检测生物技术公司QCDX的董事会成员；以及酒店控股公司Merakia的所有者。2020年4月，他成为Aikido Pharma（纳斯达克股票代码:AIKI）AI/ML（人工智能/机器学习）的顾问委员会成员。安德烈亚斯是希腊人，1963年从哥伦比亚大学获得奖学金来到美国，在那里他获得了工程和运筹学数学方法学士学位，并自1996年以来资助了一个命名的奖学金计划。他还获得了Pratt Institute的计算机科学研究生学位。他已婚，是四个孩子的父亲。
Andreas Typaldos has served as our Chairman and Chief Executive Officer since inception. Andreas has been a software and technology entrepreneur from the inception of the industry, as well as a private equity investor through a Family Office. His entrepreneurial activities and companies extend over both the US and international and primarily European venues. In the past, he was founder, founding investor, Board Member, and Chief Executive of a number of software, technology, consulting services, and internet companies, including AXS-One, an early international enterprise software company; Enikia LLC subsequently known as Arkados and Iota Communications Inc., which was a fabless semiconductor company in the powerline-based communications space at the inception of that market and whose Homeplug-compliant technology was sold to one of the largest semiconductor companies (ST Micro) before evolving into the IoT space; Xandros Inc., a Linux operating system company that provided the operating system used by Asus and Intel on the eeePC netbook mobile device to create that space prior to its domination by Apple’s iPad tablet; and a number of other companies in the technology, software, AI, and lifestyle markets. Currently, he is the Executive Chairman of BCII Enterprises Inc., a publicly traded holding company with a number of software, CLOUD, and AI operating subsidiaries including Soteria Health, a digital health and virtual care company of which he acts as Chairman; and Executive Chairman of Scalix Inc., a Linux-based enterprise email server company developed through funding and technology support by Microsoft. In the lifestyle and life sciences related industries, he is Board Member of an early cancer detection biotech company, QCDx; and owner of Merakia, a hospitality holding company. In April 2020 he became an Advisory Board Member, for AI/ML (artificial intelligence/machine learning), of AIkido Pharma (NASDAQ:AIKI). A native of Greece, Andreas came to the US in 1963 on scholarship from Columbia University where he received a Bachelors degree in Mathematical Methods for Engineering and Operations Research and where he has funded a named scholarship program since 1996. He also received a graduate degree in Computer Science from Pratt Institute. He is married and is the father of four. - Andreas Typaldos自公司成立起担任董事长兼首席执行官。安德烈亚斯从软件和技术行业一开始就是一位企业家，同时也是一家家族办公室的私人股本投资者。他的创业活动和公司遍及美国和国际，主要是欧洲。过去，他曾是许多软件，技术，咨询服务和互联网公司的创始人，创始投资者，董事会成员兼首席执行官，其中包括早期的国际企业软件公司AXS-One；Enikia LLC随后被称为Arkados和Iota Communications Inc.，Xandros Inc.是一家基于Powerline的通信领域的无晶圆厂半导体公司，在进入物联网领域之前，其兼容HomePlug的技术被出售给了最大的半导体公司之一（ST Micro），一家Linux操作系统公司，提供华硕和英特尔在EeePC上网本移动设备上使用的操作系统，以在被苹果iPad平板电脑统治之前创建该空间；以及技术，软件，AI和生活方式市场上的其他一些公司。目前，他是BCII Enterprises Inc.的执行主席，BCII Enterprises Inc.是一家上市控股公司，拥有许多软件，云和AI运营子公司，包括他担任董事长的数字健康和虚拟护理公司Soteria Health；和Scalix Inc.的执行主席，一家基于Linux的企业电子邮件服务器公司，由微软提供资金和技术支持。在生活方式和生命科学相关行业，他是早期癌症检测生物技术公司QCDX的董事会成员；以及酒店控股公司Merakia的所有者。2020年4月，他成为Aikido Pharma（纳斯达克股票代码:AIKI）AI/ML（人工智能/机器学习）的顾问委员会成员。安德烈亚斯是希腊人，1963年从哥伦比亚大学获得奖学金来到美国，在那里他获得了工程和运筹学数学方法学士学位，并自1996年以来资助了一个命名的奖学金计划。他还获得了Pratt Institute的计算机科学研究生学位。他已婚，是四个孩子的父亲。
- Andreas Typaldos has served as our Chairman and Chief Executive Officer since inception. Andreas has been a software and technology entrepreneur from the inception of the industry, as well as a private equity investor through a Family Office. His entrepreneurial activities and companies extend over both the US and international and primarily European venues. In the past, he was founder, founding investor, Board Member, and Chief Executive of a number of software, technology, consulting services, and internet companies, including AXS-One, an early international enterprise software company; Enikia LLC subsequently known as Arkados and Iota Communications Inc., which was a fabless semiconductor company in the powerline-based communications space at the inception of that market and whose Homeplug-compliant technology was sold to one of the largest semiconductor companies (ST Micro) before evolving into the IoT space; Xandros Inc., a Linux operating system company that provided the operating system used by Asus and Intel on the eeePC netbook mobile device to create that space prior to its domination by Apple’s iPad tablet; and a number of other companies in the technology, software, AI, and lifestyle markets. Currently, he is the Executive Chairman of BCII Enterprises Inc., a publicly traded holding company with a number of software, CLOUD, and AI operating subsidiaries including Soteria Health, a digital health and virtual care company of which he acts as Chairman; and Executive Chairman of Scalix Inc., a Linux-based enterprise email server company developed through funding and technology support by Microsoft. In the lifestyle and life sciences related industries, he is Board Member of an early cancer detection biotech company, QCDx; and owner of Merakia, a hospitality holding company. In April 2020 he became an Advisory Board Member, for AI/ML (artificial intelligence/machine learning), of AIkido Pharma (NASDAQ:AIKI). A native of Greece, Andreas came to the US in 1963 on scholarship from Columbia University where he received a Bachelors degree in Mathematical Methods for Engineering and Operations Research and where he has funded a named scholarship program since 1996. He also received a graduate degree in Computer Science from Pratt Institute. He is married and is the father of four.
- Sean Fitzpatrick
-
Sean Fitzpatrick自成立以来一直是我们的首席财务官和董事会成员。他是FIDEM Advisors的创始合伙人，FIDEM Advisors是一家精品咨询公司，提供筹集股本，债务和桥梁资本的服务。肖恩拥有超过25年的华尔街经验，涉及多家主要投资银行。他的职业生涯始于1990年，在Shearson Lehman Brothers担任财务顾问。Sean在Alex Brown and Sons，Hambrecht&Quist，JP Morgan和Credit Suisse担任过各种职责不断增加的职位。他的大部分工作经验都集中在私人财富，家族理财室和机构客户的管理和筹集资金上。在他的整个职业生涯中，肖恩代表不同的客户基础筹集或管理了超过20亿美元。他拥有马里兰州巴尔的摩Loyola大学的金融学学士学位。
Sean Fitzpatrick has been our Chief Financial Officer and Board Member since inception. He is the Founding Partner of Fidem Advisors, a boutique advisory firm that offers services in raising equity, debt, and bridge capital. Sean has over 25 years of Wall Street experience, spanning several major investment banks. He began his career in 1990 with Shearson Lehman Brothers as a Financial Advisor. Sean has held various positions of increasing responsibility at Alex Brown and Sons, Hambrecht & Quist, JP Morgan and Credit Suisse. The majority of his work experience has focused on the managing and raising capital from private wealth, family offices and institutional clients. Throughout the course of his career, Sean has raised or managed in excess of $2 billion dollars on behalf of a diverse base of clients. He holds a BBA in Finance from Loyola University in Baltimore, MD. - Sean Fitzpatrick自成立以来一直是我们的首席财务官和董事会成员。他是FIDEM Advisors的创始合伙人，FIDEM Advisors是一家精品咨询公司，提供筹集股本，债务和桥梁资本的服务。肖恩拥有超过25年的华尔街经验，涉及多家主要投资银行。他的职业生涯始于1990年，在Shearson Lehman Brothers担任财务顾问。Sean在Alex Brown and Sons，Hambrecht&Quist，JP Morgan和Credit Suisse担任过各种职责不断增加的职位。他的大部分工作经验都集中在私人财富，家族理财室和机构客户的管理和筹集资金上。在他的整个职业生涯中，肖恩代表不同的客户基础筹集或管理了超过20亿美元。他拥有马里兰州巴尔的摩Loyola大学的金融学学士学位。
- Sean Fitzpatrick has been our Chief Financial Officer and Board Member since inception. He is the Founding Partner of Fidem Advisors, a boutique advisory firm that offers services in raising equity, debt, and bridge capital. Sean has over 25 years of Wall Street experience, spanning several major investment banks. He began his career in 1990 with Shearson Lehman Brothers as a Financial Advisor. Sean has held various positions of increasing responsibility at Alex Brown and Sons, Hambrecht & Quist, JP Morgan and Credit Suisse. The majority of his work experience has focused on the managing and raising capital from private wealth, family offices and institutional clients. Throughout the course of his career, Sean has raised or managed in excess of $2 billion dollars on behalf of a diverse base of clients. He holds a BBA in Finance from Loyola University in Baltimore, MD.
- Robert Nicholson
-
Robert Nicholson自成立以来一直担任董事会成员。Robert在投资银行和私募股权领域拥有多年的领导和投资经验，专注于公共和私人资本市场交易，房地产，并购和中端市场信贷。他目前是Archon的主要所有者和董事总经理，负责公司的运营，并购，财务咨询，资本发展和战略增长的一般管理。他于2019年从德意志银行加入Archon，专注于私募股权和另类投资。罗伯特的职业生涯始于摩根士丹利的分析师，之后进入牛津大学的买方分析，最终进入富国房地产基金的收购。在过去的15年中，他直接或通过与行业中一些最大的私募股权公司（包括Hines，Cole Capital，Apollo和Ares Management）的合资企业在资本市场任职。他拥有德克萨斯大学奥斯汀分校（University of Texas at Austin）的经济学学士学位，伦敦商学院（London Business School）的专注于私人股本的硕士学位以及哥伦比亚商学院（Columbia Business School）的专注于金融的MBA学位。
Robert Nicholson has served as a member of the Board of Directors since inception. Robert has many years of leadership and investing experience in investment banking and private equity with a focus on public and private Capital Markets transactions, Real Estate, Mergers and Acquisitions, and Mid-Market Credit. He is currently a principal owner and Managing Director of Archon, responsible for general management of the firm’s operations, mergers and acquisitions, financial advisory, capital development, and strategic growth. He joined Archon in 2019 from Deutsche Bank where he focused on Private Equity and Alternative Investments. Robert began his career as an analyst at Morgan Stanley before moving into buy-side analysis with Oxford, and eventually into acquisitions for Wells Real Estate Funds. Over the last 15 years he has worked in a capital markets role directly or through joint ventures with some of the largest Private Equity firms in the industry including Hines, Cole Capital, Apollo, and Ares Management. He has a BA in Economics from the University of Texas at Austin, a Masters from London Business School with a concentration in Private Equity, and an MBA from Columbia Business School with a concentration in Finance. - Robert Nicholson自成立以来一直担任董事会成员。Robert在投资银行和私募股权领域拥有多年的领导和投资经验，专注于公共和私人资本市场交易，房地产，并购和中端市场信贷。他目前是Archon的主要所有者和董事总经理，负责公司的运营，并购，财务咨询，资本发展和战略增长的一般管理。他于2019年从德意志银行加入Archon，专注于私募股权和另类投资。罗伯特的职业生涯始于摩根士丹利的分析师，之后进入牛津大学的买方分析，最终进入富国房地产基金的收购。在过去的15年中，他直接或通过与行业中一些最大的私募股权公司（包括Hines，Cole Capital，Apollo和Ares Management）的合资企业在资本市场任职。他拥有德克萨斯大学奥斯汀分校（University of Texas at Austin）的经济学学士学位，伦敦商学院（London Business School）的专注于私人股本的硕士学位以及哥伦比亚商学院（Columbia Business School）的专注于金融的MBA学位。
- Robert Nicholson has served as a member of the Board of Directors since inception. Robert has many years of leadership and investing experience in investment banking and private equity with a focus on public and private Capital Markets transactions, Real Estate, Mergers and Acquisitions, and Mid-Market Credit. He is currently a principal owner and Managing Director of Archon, responsible for general management of the firm’s operations, mergers and acquisitions, financial advisory, capital development, and strategic growth. He joined Archon in 2019 from Deutsche Bank where he focused on Private Equity and Alternative Investments. Robert began his career as an analyst at Morgan Stanley before moving into buy-side analysis with Oxford, and eventually into acquisitions for Wells Real Estate Funds. Over the last 15 years he has worked in a capital markets role directly or through joint ventures with some of the largest Private Equity firms in the industry including Hines, Cole Capital, Apollo, and Ares Management. He has a BA in Economics from the University of Texas at Austin, a Masters from London Business School with a concentration in Private Equity, and an MBA from Columbia Business School with a concentration in Finance.
- William Carson
-
德克萨斯州的威廉·卡森（William Carson）自2021年2月22日起担任董事，在处方和OTC药品行业拥有40年的管理经验，广泛接触产品许可，新产品研发，制造，RX到OTC交换机，公司收购和新业务实体发展。他曾担任Novartis，Bayer，Galderma公司的领导职务，涉及MTO工厂管理、新设施建设、合规、产品开发和监管事务（NDA、ANDA、RX TO OTC Switch、OTC Monographs）、LMA（尽职调查、组织审查、并购后整合）。在过去的9年中，Carson经营自己的咨询业务，承担以下咨询任务:合规性，生产，许可和收购产品开发以及FDA/监管战略。Carson的职业生涯始于Sandoz Pharmaceuticals的Dorsey Laboratories部门，从1972年到1994年，他一直受雇于该部门；他担任过各种董事职务，例如监管事务总监和新产品总监。他最后担任科学事务副总裁，管理TAVIST-1和TAVIST-D从RX到OTC地位的FDA批准过程。从1994年到1996年，他曾担任Goldline Pharmaceuticals公司的OTC产品高级副总裁。从1996年到2004年，他曾担任Bayer Consumer Care Division（NYSE:BAYRY）的副总裁，负责科学事务。从2004年到2011年，他曾担任Galderma Laboratories（皮肤健康制药公司）的医疗和监管事务高级副总裁。在那里，他建立了部门，以支持一段时间的快速销售增长，新产品的批准和收购。他还曾担任两项重大收购整合的团队负责人，即美国的Collagenix和欧洲的Q-Med。Carson先生拥有内布拉斯加大学生理学和生物化学学士和硕士学位。
William Carson,of Texas, has been a director since February 22 2021 and is a forty year management veteran in the prescription and OTC drug industries with broad exposure to product licensing, new product R&D, manufacturing, Rx-to-OTC switches, company acquisition and new business entity development. He has held Leadership roles at Novartis, Bayer, Galderma, in MTO Plant Management, New Facility Construction, Compliance, Product Development and Regulatory Affairs (NDA, ANDA, RX to OTC Switch, OTC Monographs), and LMA (Due Diligence, Organizational Review, Post Merger/Acquisition Integration). For the past 9 years, Carson has operated his own consulting business taking on consulting assignments in: compliance, production, licensing and acquisition product development and FDA/regulatory strategy. Carson started his career with Dorsey Laboratories Division, Sandoz Pharmaceuticals where he remained employed from 1972-1994 ; he served in a variety of director roles such as Director of Regulatory Affairs, and Director of New Products. He last served as Vice President of Scientific Affairs, managing the FDA approval process for the switches of Tavist-1 and Tavist-D from Rx to OTC status. From 1994-1996 he served as Senior Vice President of OTC Products at Goldline Pharmaecuticals. From 1996-2004 he was Vice President, Scientific Affairs with Bayer Consumer Care Division (NYSE: BAYRY). From 2004-2011 he served as Senior Vice-President, Medical &Regulatory Affairs at Galderma Laboratories, a skin health pharma company. There he built departments to support a period of rapid sales growth, new product approvals and acquisitions. He also was the team leader for the integration of two major acquisitions, Collagenix in the U.S. and Q-Med in Europe. Mr. Carson has a BS and MS from University of Nebraska in Physiology and Biochemistry. - 德克萨斯州的威廉·卡森（William Carson）自2021年2月22日起担任董事，在处方和OTC药品行业拥有40年的管理经验，广泛接触产品许可，新产品研发，制造，RX到OTC交换机，公司收购和新业务实体发展。他曾担任Novartis，Bayer，Galderma公司的领导职务，涉及MTO工厂管理、新设施建设、合规、产品开发和监管事务（NDA、ANDA、RX TO OTC Switch、OTC Monographs）、LMA（尽职调查、组织审查、并购后整合）。在过去的9年中，Carson经营自己的咨询业务，承担以下咨询任务:合规性，生产，许可和收购产品开发以及FDA/监管战略。Carson的职业生涯始于Sandoz Pharmaceuticals的Dorsey Laboratories部门，从1972年到1994年，他一直受雇于该部门；他担任过各种董事职务，例如监管事务总监和新产品总监。他最后担任科学事务副总裁，管理TAVIST-1和TAVIST-D从RX到OTC地位的FDA批准过程。从1994年到1996年，他曾担任Goldline Pharmaceuticals公司的OTC产品高级副总裁。从1996年到2004年，他曾担任Bayer Consumer Care Division（NYSE:BAYRY）的副总裁，负责科学事务。从2004年到2011年，他曾担任Galderma Laboratories（皮肤健康制药公司）的医疗和监管事务高级副总裁。在那里，他建立了部门，以支持一段时间的快速销售增长，新产品的批准和收购。他还曾担任两项重大收购整合的团队负责人，即美国的Collagenix和欧洲的Q-Med。Carson先生拥有内布拉斯加大学生理学和生物化学学士和硕士学位。
- William Carson,of Texas, has been a director since February 22 2021 and is a forty year management veteran in the prescription and OTC drug industries with broad exposure to product licensing, new product R&D, manufacturing, Rx-to-OTC switches, company acquisition and new business entity development. He has held Leadership roles at Novartis, Bayer, Galderma, in MTO Plant Management, New Facility Construction, Compliance, Product Development and Regulatory Affairs (NDA, ANDA, RX to OTC Switch, OTC Monographs), and LMA (Due Diligence, Organizational Review, Post Merger/Acquisition Integration). For the past 9 years, Carson has operated his own consulting business taking on consulting assignments in: compliance, production, licensing and acquisition product development and FDA/regulatory strategy. Carson started his career with Dorsey Laboratories Division, Sandoz Pharmaceuticals where he remained employed from 1972-1994 ; he served in a variety of director roles such as Director of Regulatory Affairs, and Director of New Products. He last served as Vice President of Scientific Affairs, managing the FDA approval process for the switches of Tavist-1 and Tavist-D from Rx to OTC status. From 1994-1996 he served as Senior Vice President of OTC Products at Goldline Pharmaecuticals. From 1996-2004 he was Vice President, Scientific Affairs with Bayer Consumer Care Division (NYSE: BAYRY). From 2004-2011 he served as Senior Vice-President, Medical &Regulatory Affairs at Galderma Laboratories, a skin health pharma company. There he built departments to support a period of rapid sales growth, new product approvals and acquisitions. He also was the team leader for the integration of two major acquisitions, Collagenix in the U.S. and Q-Med in Europe. Mr. Carson has a BS and MS from University of Nebraska in Physiology and Biochemistry.
- Anthony Hayes
-
Anthony Hayes，在2013年成为一名董事和首席执行官；2013年3月以来一直担任南北分区的首席执行官；自2013年6月以来一直担任公司的顾问。从2012年8月至2013年8月，Hayes先生是JaNSOME IP Management LLC 以及 JaNSOME Patent Fund LP的基金管理人，这两个公司都是由他共同创立的。Hayes先生创立了Atwater Partners of Texas LLC，并于2010年3月到2013年8月担任其管理人员，1999年5月到2010年3月，他是 Nelson Mullins Riley & Scarborough LLP的合伙人。Hayes先生从Tulane University School of Law取得了法学博士学位，从华盛顿玛丽学院（Mary Washington College）取得经济学学士学位。
Anthony Hayes has served as a director and Chief Executive Officer since 2013. Mr. Hayes also serves as Chairman of SIM Acquisition Corp. I (NASDAQ: SIMAU, SIMA, SIMAW), a blank check company, which completed its initial public offering in July 2024 and raised aggregate proceeds of $230 million. Before his role at Dominari, Mr. Hayes was a partner at Nelson Mullins, an Am Law 100 law firm, from May 1999 to March 2010. His legal expertise and business acumen have been recognized through various accolades including by President George W. Bush who gave Mr. Hayes special recognition for creating the Wills for Heroes program, a national 501(c)(3), in response to the September 11 attacks (willsforheroes.com), and his work, "Avoiding the Post Crisis Crisis: How to Prevent Post Crisis Donation for Victims from Leading to Litigation", was published in the ICMA Journal (ICMA Journal, January/February 2008). Other honors include IAM IP Personality of 2013, American Board of Trial Advocates Young Lawyer of the Year and "20 Under 40" in Columbia, South Carolina. Mr. Hayes received his Juris Doctor from Tulane University Law School in May 1995, a Bachelor of Arts in economics from Mary Washington College in May 1990, and he is a member of the bar in the District of Columbia, Florida, New York, and South Mr. Hayes received his Juris Doctorate from Tulane University School of Law and his B.A. in economics from Mary Washington College. - Anthony Hayes，在2013年成为一名董事和首席执行官；2013年3月以来一直担任南北分区的首席执行官；自2013年6月以来一直担任公司的顾问。从2012年8月至2013年8月，Hayes先生是JaNSOME IP Management LLC 以及 JaNSOME Patent Fund LP的基金管理人，这两个公司都是由他共同创立的。Hayes先生创立了Atwater Partners of Texas LLC，并于2010年3月到2013年8月担任其管理人员，1999年5月到2010年3月，他是 Nelson Mullins Riley & Scarborough LLP的合伙人。Hayes先生从Tulane University School of Law取得了法学博士学位，从华盛顿玛丽学院（Mary Washington College）取得经济学学士学位。
- Anthony Hayes has served as a director and Chief Executive Officer since 2013. Mr. Hayes also serves as Chairman of SIM Acquisition Corp. I (NASDAQ: SIMAU, SIMA, SIMAW), a blank check company, which completed its initial public offering in July 2024 and raised aggregate proceeds of $230 million. Before his role at Dominari, Mr. Hayes was a partner at Nelson Mullins, an Am Law 100 law firm, from May 1999 to March 2010. His legal expertise and business acumen have been recognized through various accolades including by President George W. Bush who gave Mr. Hayes special recognition for creating the Wills for Heroes program, a national 501(c)(3), in response to the September 11 attacks (willsforheroes.com), and his work, "Avoiding the Post Crisis Crisis: How to Prevent Post Crisis Donation for Victims from Leading to Litigation", was published in the ICMA Journal (ICMA Journal, January/February 2008). Other honors include IAM IP Personality of 2013, American Board of Trial Advocates Young Lawyer of the Year and "20 Under 40" in Columbia, South Carolina. Mr. Hayes received his Juris Doctor from Tulane University Law School in May 1995, a Bachelor of Arts in economics from Mary Washington College in May 1990, and he is a member of the bar in the District of Columbia, Florida, New York, and South Mr. Hayes received his Juris Doctorate from Tulane University School of Law and his B.A. in economics from Mary Washington College.
高管简历
中英对照 | 中文 | 英文- Andreas Typaldos
Andreas Typaldos自公司成立起担任董事长兼首席执行官。安德烈亚斯从软件和技术行业一开始就是一位企业家，同时也是一家家族办公室的私人股本投资者。他的创业活动和公司遍及美国和国际，主要是欧洲。过去，他曾是许多软件，技术，咨询服务和互联网公司的创始人，创始投资者，董事会成员兼首席执行官，其中包括早期的国际企业软件公司AXS-One；Enikia LLC随后被称为Arkados和Iota Communications Inc.，Xandros Inc.是一家基于Powerline的通信领域的无晶圆厂半导体公司，在进入物联网领域之前，其兼容HomePlug的技术被出售给了最大的半导体公司之一（ST Micro），一家Linux操作系统公司，提供华硕和英特尔在EeePC上网本移动设备上使用的操作系统，以在被苹果iPad平板电脑统治之前创建该空间；以及技术，软件，AI和生活方式市场上的其他一些公司。目前，他是BCII Enterprises Inc.的执行主席，BCII Enterprises Inc.是一家上市控股公司，拥有许多软件，云和AI运营子公司，包括他担任董事长的数字健康和虚拟护理公司Soteria Health；和Scalix Inc.的执行主席，一家基于Linux的企业电子邮件服务器公司，由微软提供资金和技术支持。在生活方式和生命科学相关行业，他是早期癌症检测生物技术公司QCDX的董事会成员；以及酒店控股公司Merakia的所有者。2020年4月，他成为Aikido Pharma（纳斯达克股票代码:AIKI）AI/ML（人工智能/机器学习）的顾问委员会成员。安德烈亚斯是希腊人，1963年从哥伦比亚大学获得奖学金来到美国，在那里他获得了工程和运筹学数学方法学士学位，并自1996年以来资助了一个命名的奖学金计划。他还获得了Pratt Institute的计算机科学研究生学位。他已婚，是四个孩子的父亲。
Andreas Typaldos has served as our Chairman and Chief Executive Officer since inception. Andreas has been a software and technology entrepreneur from the inception of the industry, as well as a private equity investor through a Family Office. His entrepreneurial activities and companies extend over both the US and international and primarily European venues. In the past, he was founder, founding investor, Board Member, and Chief Executive of a number of software, technology, consulting services, and internet companies, including AXS-One, an early international enterprise software company; Enikia LLC subsequently known as Arkados and Iota Communications Inc., which was a fabless semiconductor company in the powerline-based communications space at the inception of that market and whose Homeplug-compliant technology was sold to one of the largest semiconductor companies (ST Micro) before evolving into the IoT space; Xandros Inc., a Linux operating system company that provided the operating system used by Asus and Intel on the eeePC netbook mobile device to create that space prior to its domination by Apple’s iPad tablet; and a number of other companies in the technology, software, AI, and lifestyle markets. Currently, he is the Executive Chairman of BCII Enterprises Inc., a publicly traded holding company with a number of software, CLOUD, and AI operating subsidiaries including Soteria Health, a digital health and virtual care company of which he acts as Chairman; and Executive Chairman of Scalix Inc., a Linux-based enterprise email server company developed through funding and technology support by Microsoft. In the lifestyle and life sciences related industries, he is Board Member of an early cancer detection biotech company, QCDx; and owner of Merakia, a hospitality holding company. In April 2020 he became an Advisory Board Member, for AI/ML (artificial intelligence/machine learning), of AIkido Pharma (NASDAQ:AIKI). A native of Greece, Andreas came to the US in 1963 on scholarship from Columbia University where he received a Bachelors degree in Mathematical Methods for Engineering and Operations Research and where he has funded a named scholarship program since 1996. He also received a graduate degree in Computer Science from Pratt Institute. He is married and is the father of four.- Andreas Typaldos自公司成立起担任董事长兼首席执行官。安德烈亚斯从软件和技术行业一开始就是一位企业家，同时也是一家家族办公室的私人股本投资者。他的创业活动和公司遍及美国和国际，主要是欧洲。过去，他曾是许多软件，技术，咨询服务和互联网公司的创始人，创始投资者，董事会成员兼首席执行官，其中包括早期的国际企业软件公司AXS-One；Enikia LLC随后被称为Arkados和Iota Communications Inc.，Xandros Inc.是一家基于Powerline的通信领域的无晶圆厂半导体公司，在进入物联网领域之前，其兼容HomePlug的技术被出售给了最大的半导体公司之一（ST Micro），一家Linux操作系统公司，提供华硕和英特尔在EeePC上网本移动设备上使用的操作系统，以在被苹果iPad平板电脑统治之前创建该空间；以及技术，软件，AI和生活方式市场上的其他一些公司。目前，他是BCII Enterprises Inc.的执行主席，BCII Enterprises Inc.是一家上市控股公司，拥有许多软件，云和AI运营子公司，包括他担任董事长的数字健康和虚拟护理公司Soteria Health；和Scalix Inc.的执行主席，一家基于Linux的企业电子邮件服务器公司，由微软提供资金和技术支持。在生活方式和生命科学相关行业，他是早期癌症检测生物技术公司QCDX的董事会成员；以及酒店控股公司Merakia的所有者。2020年4月，他成为Aikido Pharma（纳斯达克股票代码:AIKI）AI/ML（人工智能/机器学习）的顾问委员会成员。安德烈亚斯是希腊人，1963年从哥伦比亚大学获得奖学金来到美国，在那里他获得了工程和运筹学数学方法学士学位，并自1996年以来资助了一个命名的奖学金计划。他还获得了Pratt Institute的计算机科学研究生学位。他已婚，是四个孩子的父亲。
- Andreas Typaldos has served as our Chairman and Chief Executive Officer since inception. Andreas has been a software and technology entrepreneur from the inception of the industry, as well as a private equity investor through a Family Office. His entrepreneurial activities and companies extend over both the US and international and primarily European venues. In the past, he was founder, founding investor, Board Member, and Chief Executive of a number of software, technology, consulting services, and internet companies, including AXS-One, an early international enterprise software company; Enikia LLC subsequently known as Arkados and Iota Communications Inc., which was a fabless semiconductor company in the powerline-based communications space at the inception of that market and whose Homeplug-compliant technology was sold to one of the largest semiconductor companies (ST Micro) before evolving into the IoT space; Xandros Inc., a Linux operating system company that provided the operating system used by Asus and Intel on the eeePC netbook mobile device to create that space prior to its domination by Apple’s iPad tablet; and a number of other companies in the technology, software, AI, and lifestyle markets. Currently, he is the Executive Chairman of BCII Enterprises Inc., a publicly traded holding company with a number of software, CLOUD, and AI operating subsidiaries including Soteria Health, a digital health and virtual care company of which he acts as Chairman; and Executive Chairman of Scalix Inc., a Linux-based enterprise email server company developed through funding and technology support by Microsoft. In the lifestyle and life sciences related industries, he is Board Member of an early cancer detection biotech company, QCDx; and owner of Merakia, a hospitality holding company. In April 2020 he became an Advisory Board Member, for AI/ML (artificial intelligence/machine learning), of AIkido Pharma (NASDAQ:AIKI). A native of Greece, Andreas came to the US in 1963 on scholarship from Columbia University where he received a Bachelors degree in Mathematical Methods for Engineering and Operations Research and where he has funded a named scholarship program since 1996. He also received a graduate degree in Computer Science from Pratt Institute. He is married and is the father of four.
- Sean Fitzpatrick
Sean Fitzpatrick自成立以来一直是我们的首席财务官和董事会成员。他是FIDEM Advisors的创始合伙人，FIDEM Advisors是一家精品咨询公司，提供筹集股本，债务和桥梁资本的服务。肖恩拥有超过25年的华尔街经验，涉及多家主要投资银行。他的职业生涯始于1990年，在Shearson Lehman Brothers担任财务顾问。Sean在Alex Brown and Sons，Hambrecht&Quist，JP Morgan和Credit Suisse担任过各种职责不断增加的职位。他的大部分工作经验都集中在私人财富，家族理财室和机构客户的管理和筹集资金上。在他的整个职业生涯中，肖恩代表不同的客户基础筹集或管理了超过20亿美元。他拥有马里兰州巴尔的摩Loyola大学的金融学学士学位。
Sean Fitzpatrick has been our Chief Financial Officer and Board Member since inception. He is the Founding Partner of Fidem Advisors, a boutique advisory firm that offers services in raising equity, debt, and bridge capital. Sean has over 25 years of Wall Street experience, spanning several major investment banks. He began his career in 1990 with Shearson Lehman Brothers as a Financial Advisor. Sean has held various positions of increasing responsibility at Alex Brown and Sons, Hambrecht & Quist, JP Morgan and Credit Suisse. The majority of his work experience has focused on the managing and raising capital from private wealth, family offices and institutional clients. Throughout the course of his career, Sean has raised or managed in excess of $2 billion dollars on behalf of a diverse base of clients. He holds a BBA in Finance from Loyola University in Baltimore, MD.- Sean Fitzpatrick自成立以来一直是我们的首席财务官和董事会成员。他是FIDEM Advisors的创始合伙人，FIDEM Advisors是一家精品咨询公司，提供筹集股本，债务和桥梁资本的服务。肖恩拥有超过25年的华尔街经验，涉及多家主要投资银行。他的职业生涯始于1990年，在Shearson Lehman Brothers担任财务顾问。Sean在Alex Brown and Sons，Hambrecht&Quist，JP Morgan和Credit Suisse担任过各种职责不断增加的职位。他的大部分工作经验都集中在私人财富，家族理财室和机构客户的管理和筹集资金上。在他的整个职业生涯中，肖恩代表不同的客户基础筹集或管理了超过20亿美元。他拥有马里兰州巴尔的摩Loyola大学的金融学学士学位。
- Sean Fitzpatrick has been our Chief Financial Officer and Board Member since inception. He is the Founding Partner of Fidem Advisors, a boutique advisory firm that offers services in raising equity, debt, and bridge capital. Sean has over 25 years of Wall Street experience, spanning several major investment banks. He began his career in 1990 with Shearson Lehman Brothers as a Financial Advisor. Sean has held various positions of increasing responsibility at Alex Brown and Sons, Hambrecht & Quist, JP Morgan and Credit Suisse. The majority of his work experience has focused on the managing and raising capital from private wealth, family offices and institutional clients. Throughout the course of his career, Sean has raised or managed in excess of $2 billion dollars on behalf of a diverse base of clients. He holds a BBA in Finance from Loyola University in Baltimore, MD.